SNTI|EPS -$0.53|Rev $22,000|Net Loss $14.5MSenti Biosciences, Inc. reported a narrower quarterly loss as the clinical stage biotechnology company continues developing its gene circuit platform therapies for incurable diseases. The company posted a loss per share of $0.53 for the fourth quarter of 2025, an improvement of 20.9% from the $0.67 loss per share recorded in the same period last year.
The company generated revenue of $22,000 for the quarter while reporting a net loss of $14.5M. Senti specializes in engineering cell and gene therapies using proprietary gene circuit platform technologies, an emerging area of biotechnology that requires substantial research and development investment before commercialization.
Wall Street maintains a bullish stance on the biotech firm despite its current losses, with analyst consensus showing 9 buy ratings and 1 hold rating, with no sell recommendations. The positive sentiment reflects confidence in the company’s pipeline of engineered therapies targeting patients with conditions that currently lack effective treatment options.
The company remains in the clinical development stage, focusing resources on advancing its therapeutic candidates through regulatory trials. Like many biotechnology companies at this phase, Senti continues to operate at a loss while building out its platform and advancing programs toward potential market approval.
This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may receive compensation from companies mentioned in this article. This content is for informational purposes only and should not be considered investment advice.